Affordable Access

A systematic evaluation of solubility enhancing excipients to enable the generation of permeability data for poorly soluble compounds in Caco-2 model.

Authors
  • Shah, Devang
  • Paruchury, Sundeep
  • Matta, Muralikrishna
  • Chowan, Gajendra
  • Subramanian, Murali
  • Saxena, Ajay
  • Soars, Matthew G
  • Herbst, John
  • Haskell, Roy
  • Marathe, Punit
  • Mandlekar, Sandhya1
  • 1 Pharmaceutical candidate optimization, Biocon Bristol-Myers Squibb R&D Center, Syngene International Limited, Biocon Park Plot 2 & 3, Bommasandra IV Phase, Bangalore - 560 099, India. [email protected] , (India)
Type
Published Article
Journal
Drug metabolism letters
Publication Date
Jan 01, 2014
Volume
8
Issue
2
Pages
109–118
Identifiers
PMID: 25429513
Source
Medline
License
Unknown

Abstract

The study presented here identified and utilized a panel of solubility enhancing excipients to enable the generation of flux data in the Human colon carcinoma (Caco-2) system for compounds with poor solubility. Solubility enhancing excipients Dimethyl acetamide (DMA) 1 % v/v, polyethylene glycol (PEG) 400 1% v/v, povidone 1% w/v, poloxamer 188 2.5% w/v and bovine serum albumin (BSA) 4% w/v did not compromise Caco-2 monolayer integrity as assessed by trans-epithelial resistance measurement (TEER) and Lucifer yellow (LY) permeation. Further, these excipients did not affect P-glycoprotein (P-gp) mediated bidirectional transport of digoxin, permeabilities of high (propranolol) or low permeability (atenolol) compounds, and were found to be inert to Breast cancer resistant protein (BCRP) mediated transport of cladribine. This approach was validated further using poorly soluble tool compounds, atazanavir (poloxamer 188 2.5% w/v) and cyclosporine A (BSA 4% w/v) and also applied to new chemical entity (NCE) BMS-A in BSA 4% w/v, for which Caco-2 data could not be generated using the traditional methodology due to poor solubility (<1 µM) in conventional Hanks balanced salt solution (HBSS). Poloxamer 188 2.5% w/v increased solubility of atazanavir by >8 fold whereas BSA 4% w/v increased the solubility of cyclosporine A and BMS-A by >2-4 fold thereby enabling permeability as well as efflux liability estimation in the Caco-2 model with reasonable recovery values. To conclude, addition of excipients such as poloxamer 188 2.5% w/v and BSA 4% w/v to HBSS leads to a significant improvement in the solubility of the poorly soluble compounds resulting in enhanced recoveries without modulating transporter-mediated efflux, expanding the applicability of Caco-2 assays to poorly soluble compounds.

Report this publication

Statistics

Seen <100 times